The Department of Health and Human Services via the National Institute of Allergy & Infectious Diseases (NIAID) has recently awarded four major contracts to further the “Development of Therapeutic Medical Countermeasures for Biodefense and Emerging Infectious Diseases”.
The following companies will receive funding under a Broad Agency Announcement (BAA) for broad spectrum countermeasures announced in June 2012:
- Aridis Pharmaceuticals, LLC $14,527,800
- Trius Therapeutics (recently acquired by Cubist Pharmaceuticals) $19,758,137
- BioCryst Pharmaceuticals, Inc. $21,956,107
- VenatoRx Pharmaceuticals Inc. $21,232,922
The awards were announced under Solicitation Number: BAA-NIAID-DMID-NIHAI2012149.
From Our Partners
